Nomura Adjusts Samsung SDI's Price Target to KRW900,000 From KRW540,000, Keeps at Buy

RBC Upgrades Tamboran Resources to Outperform From Sector Perform, Raises Price Target to $55 From $38, Keeps Speculative Risk

Tamboran Resources (TBN) has an average rating of buy and mean price target of $57.40 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Shanghai Pharmaceuticals' Profit Climbs 6.4% in Q1

Shanghai Pharmaceuticals (SHA:601607, HKG:2607) recorded a 6.4% rise in attributable profit in the first quarter of 2026 to 1.42 billion yuan from 1.33 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.The pharma company's earnings per share rose to 0.3823 yuan from 0.3595 yuan in the corresponding period of the previous fiscal year.Revenue jumped 6.4% to 75.3 billion yuan from 70.8 billion yuan in the year-ago period.

CGI Q2 Adjusted Net Earnings $483.4M, up 0.6% YoY